Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 1;51(11):e243-e244.
doi: 10.1097/CCM.0000000000005956. Epub 2023 Oct 12.

C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study

Endry H T Lim  1   2 , Alexander P J Vlaar  1 , Matthijs C Brouwer  2 , Diederik van de Beek  2
Affiliations
Comment

C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study

Endry H T Lim et al. Crit Care Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Vlaar’s institution received funding from InflaRx paid to Amsterdam UMC, outside the submitted work. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Comment on

References

    1. Carvelli J, Vivier E: C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE. Crit Care Med. 2023; 51:e129–e130
    1. Vlaar APJ, Witzenrath M, van Paassen P, et al.; PANAMO study group: Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022; 10:1137–1146
    1. Lim EHT, van Amstel RBE, de Boer VV, et al.: Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Rev. 2023; 57:100995
    1. de Bruin S, Bos LD, van Roon MA, et al.; Amsterdam UMC COVID-19 Biobank Investigators: Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine. 2021; 67:103378
    1. Vlaar APJ, Lim EHT, de Bruin S, et al.: The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci. 2022; 15:854–858